[{"orgOrder":0,"company":"Catholic University of Korea Saint Paul's Hospital","sponsor":"National Health Insurance Service Ilsan Hospital | Medy-Tox","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Catholic University of Korea Saint Paul's Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Catholic University of Korea Saint Paul's Hospital \/ National Health Insurance Service Ilsan Hospital | Medy-Tox","highestDevelopmentStatusID":"11","companyTruncated":"Catholic University of Korea Saint Paul's Hospital \/ National Health Insurance Service Ilsan Hospital | Medy-Tox"},{"orgOrder":0,"company":"Jeffrey Alan Klein","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Jeffrey Alan Klein","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jeffrey Alan Klein \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jeffrey Alan Klein \/ Undisclosed"},{"orgOrder":0,"company":"University of Zurich","sponsor":"Swiss National Science Foundation | Fresenius Kabi AB Brunna | University Hospital Z\u00fcrich","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Alanyl Glutamine","moa":"Amino acid metabolism","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of Zurich","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Zurich \/ Swiss National Science Foundation | Fresenius Kabi AB Brunna | University Hospital Z\u00fcrich","highestDevelopmentStatusID":"11","companyTruncated":"University of Zurich \/ Swiss National Science Foundation | Fresenius Kabi AB Brunna | University Hospital Z\u00fcrich"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of North Carolina \/ Bausch Health","highestDevelopmentStatusID":"11","companyTruncated":"University of North Carolina \/ Bausch Health"},{"orgOrder":0,"company":"Texas Tech University Health Sciences Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Texas Tech University Health Sciences Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Texas Tech University Health Sciences Center \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Texas Tech University Health Sciences Center \/ Merck & Co"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"QATAR","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"University of Louisville","sponsor":"Healthpoint","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Bacitracin Zinc","moa":"C55-isoprenyl pyrophosphate","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of Louisville","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Louisville \/ Healthpoint","highestDevelopmentStatusID":"11","companyTruncated":"University of Louisville \/ Healthpoint"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"B. Braun Medical \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"GERMANY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"D-Panthenol","moa":"CHRM3","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Healthpoint","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Enzyme","year":"2012","type":"Inapplicable","leadProduct":"Collagenase Inhibitor","moa":"Collagen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Healthpoint","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healthpoint \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Healthpoint \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacoeconomic Unit","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Pharmacoeconomic Unit","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacoeconomic Unit \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pharmacoeconomic Unit \/ Undisclosed"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Techpool Bio-Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Urinastatin","moa":"enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Techpool Bio-Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Peking Union Medical College Hospital \/ Techpool Bio-Pharma"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Pharmbio Korea","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Lipase","moa":"Fatty acids","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seoul National University Hospital \/ Pharmbio Korea","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Hospital \/ Pharmbio Korea"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Wisconsin, Madison \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of Wisconsin, Madison \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University Health Network, Toronto \/ Novo Nordisk","highestDevelopmentStatusID":"11","companyTruncated":"University Health Network, Toronto \/ Novo Nordisk"},{"orgOrder":0,"company":"James J. Peters Veterans Affairs Medical Center","sponsor":"Kessler Institute for Rehabilitation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"James J. Peters Veterans Affairs Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"James J. Peters Veterans Affairs Medical Center \/ Kessler Institute for Rehabilitation","highestDevelopmentStatusID":"11","companyTruncated":"James J. Peters Veterans Affairs Medical Center \/ Kessler Institute for Rehabilitation"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endeavor Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Endeavor Health \/ Undisclosed"},{"orgOrder":0,"company":"Children's Hospital of Eastern Ontario","sponsor":"Alberta Children's Hospital | British Columbia Children's Hospital | London Health Sciences Centre | CHU Sainte-Justine | IWK Health Centre | Montreal Children's Hospital of the MUHC","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Children's Hospital of Eastern Ontario","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Children's Hospital of Eastern Ontario \/ Alberta Children's Hospital | British Columbia Children's Hospital | London Health Sciences Centre | CHU Sainte-Justine | IWK Health Centre | Montreal Children's Hospital of the MUHC","highestDevelopmentStatusID":"11","companyTruncated":"Children's Hospital of Eastern Ontario \/ Alberta Children's Hospital | British Columbia Children's Hospital | London Health Sciences Centre | CHU Sainte-Justine | IWK Health Centre | Montreal Children's Hospital of the MUHC"},{"orgOrder":0,"company":"North Memorial Health Care","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"North Memorial Health Care","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"North Memorial Health Care \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"North Memorial Health Care \/ Undisclosed"},{"orgOrder":0,"company":"Yuria-Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UKRAINE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sodium Lactate","moa":"Homeostasis","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Yuria-Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuria-Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yuria-Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Coalition for National Trauma Research","sponsor":"Cerus Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Pathogen-Reduced Plasma","moa":"Immune","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Coalition for National Trauma Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coalition for National Trauma Research \/ Cerus Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Coalition for National Trauma Research \/ Cerus Corporation"},{"orgOrder":0,"company":"First Affiliated Hospital of Wannan Medical College","sponsor":"Wuhu City Second People\u2019s Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Shenfu","moa":"Immune","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"First Affiliated Hospital of Wannan Medical College","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"First Affiliated Hospital of Wannan Medical College \/ Wuhu City Second People\u2019s Hospital","highestDevelopmentStatusID":"11","companyTruncated":"First Affiliated Hospital of Wannan Medical College \/ Wuhu City Second People\u2019s Hospital"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Vedolizumab","moa":"||Integrin alpha-4\/beta-7","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Mirikizumab","moa":"Interleukin-23","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"University of North Carolina \/ Eli Lilly"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRIA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Cerebrolysin","moa":"Neurotrophic factor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ever Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ever Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Christiana Care Health Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Christiana Care Health Services","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Christiana Care Health Services \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Christiana Care Health Services \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Diclofenac Epolamine","moa":"PTGS1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IBSA Institut Biochimique \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"IBSA Institut Biochimique \/ Undisclosed"},{"orgOrder":0,"company":"Oregon Health and Science University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Oregon Health and Science University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oregon Health and Science University \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Oregon Health and Science University \/ Merck & Co"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Merck & Co | University of Texas System | Respiratory Motion, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Merck & Co | University of Texas System | Respiratory Motion, Inc","highestDevelopmentStatusID":"11","companyTruncated":"Mayo Clinic \/ Merck & Co | University of Texas System | Respiratory Motion, Inc"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"AlloSource","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Skin Allograft","moa":"Skin barrier","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virginia Commonwealth University \/ AlloSource","highestDevelopmentStatusID":"11","companyTruncated":"Virginia Commonwealth University \/ AlloSource"},{"orgOrder":0,"company":"Orlando Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ropivacaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Orlando Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Orlando Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Orlando Health \/ Undisclosed"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Pacira BioSciences","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Pacira BioSciences"},{"orgOrder":0,"company":"Andrews Research & Education Foundation","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Andrews Research & Education Foundation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Andrews Research & Education Foundation \/ Pacira BioSciences","highestDevelopmentStatusID":"11","companyTruncated":"Andrews Research & Education Foundation \/ Pacira BioSciences"},{"orgOrder":0,"company":"Chadrick Evans","sponsor":"University of Illinois College of Medicine at Peoria | OSF Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Chadrick Evans","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Chadrick Evans \/ University of Illinois College of Medicine at Peoria | OSF Healthcare System","highestDevelopmentStatusID":"11","companyTruncated":"Chadrick Evans \/ University of Illinois College of Medicine at Peoria | OSF Healthcare System"},{"orgOrder":0,"company":"Kuopio University Hospital","sponsor":"Admescope","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FINLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Levobupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Kuopio University Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Kuopio University Hospital \/ Admescope","highestDevelopmentStatusID":"11","companyTruncated":"Kuopio University Hospital \/ Admescope"},{"orgOrder":0,"company":"Vanderbilt University","sponsor":"SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Vanderbilt University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanderbilt University \/ SHIRE PLC","highestDevelopmentStatusID":"11","companyTruncated":"Vanderbilt University \/ SHIRE PLC"},{"orgOrder":0,"company":"Kingman Regional Medical Center","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Kingman Regional Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kingman Regional Medical Center \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Kingman Regional Medical Center \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"University of Illinois, Chicago","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of Illinois, Chicago","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Illinois, Chicago \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"University of Illinois, Chicago \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"Northwestern University","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwestern University \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Northwestern University \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"University of New Mexico","sponsor":"La Jolla Pharmaceutical | National Center for Advancing Translational Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of New Mexico","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of New Mexico \/ La Jolla Pharmaceutical | National Center for Advancing Translational Sciences","highestDevelopmentStatusID":"11","companyTruncated":"University of New Mexico \/ La Jolla Pharmaceutical | National Center for Advancing Translational Sciences"},{"orgOrder":0,"company":"University of New Mexico","sponsor":"La Jolla Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Angiotensin II","moa":"Type-1 angiotensin II receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"University of New Mexico","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of New Mexico \/ La Jolla Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"University of New Mexico \/ La Jolla Pharmaceutical"},{"orgOrder":0,"company":"Gregory Gilot","sponsor":"LifeNet Health | Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Human Acellular Dermal Matrix","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Gregory Gilot","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gregory Gilot \/ LifeNet Health | Cleveland Clinic","highestDevelopmentStatusID":"11","companyTruncated":"Gregory Gilot \/ LifeNet Health | Cleveland Clinic"},{"orgOrder":0,"company":"Anders Perner, MD, PhD","sponsor":"Rigshospitalet | Centre for Research in Intensive Care | Scandinavian Critical Care Trials Group","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Isotonic Crystalloid","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Anders Perner, MD, PhD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anders Perner, MD, PhD \/ Rigshospitalet | Centre for Research in Intensive Care | Scandinavian Critical Care Trials Group","highestDevelopmentStatusID":"11","companyTruncated":"Anders Perner, MD, PhD \/ Rigshospitalet | Centre for Research in Intensive Care | Scandinavian Critical Care Trials Group"},{"orgOrder":0,"company":"CellTherX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Microsurfaced Skin Graft","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"CellTherX","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellTherX \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"CellTherX \/ Undisclosed"},{"orgOrder":0,"company":"Moleac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SINGAPORE","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Neuroaid","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Moleac","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moleac \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Moleac \/ Undisclosed"},{"orgOrder":0,"company":"Augusta University","sponsor":"NuTech Medical","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Oligonucleotide","year":"2014","type":"Inapplicable","leadProduct":"Nucel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Augusta University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Augusta University \/ NuTech Medical","highestDevelopmentStatusID":"11","companyTruncated":"Augusta University \/ NuTech Medical"},{"orgOrder":0,"company":"The Hospital for Sick Children","sponsor":"Physician Services Incorporated | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"Quadrivalent Human Papillomavirus Vaccine","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"The Hospital for Sick Children","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Pill","sponsorNew":"The Hospital for Sick Children \/ Physician Services Incorporated | Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"The Hospital for Sick Children \/ Physician Services Incorporated | Merck & Co"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Shanghai Jiaotong University School of Medicine | Beijing Children's Hospital | Third Military Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Recombinant Human GM-CSF","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Shanghai Jiaotong University School of Medicine | Beijing Children's Hospital | Third Military Medical University","highestDevelopmentStatusID":"11","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Shanghai Jiaotong University School of Medicine | Beijing Children's Hospital | Third Military Medical University"},{"orgOrder":0,"company":"Rigshospitalet","sponsor":"Octapharma","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Ringer-acetat","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Rigshospitalet","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigshospitalet \/ Octapharma","highestDevelopmentStatusID":"11","companyTruncated":"Rigshospitalet \/ Octapharma"},{"orgOrder":0,"company":"St. Louis University","sponsor":"Next Science","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Surgx Wound Gel","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"St. Louis University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Gel","sponsorNew":"St. Louis University \/ Next Science","highestDevelopmentStatusID":"11","companyTruncated":"St. Louis University \/ Next Science"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Volulyte","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Intermountain Health","sponsor":"University of Utah","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Arginine Vasopressin","moa":"Vasopressin receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Intermountain Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intermountain Health \/ University of Utah","highestDevelopmentStatusID":"11","companyTruncated":"Intermountain Health \/ University of Utah"},{"orgOrder":0,"company":"BTG INTERNATIONAL INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Crotalidae Immune Fab","moa":"Venom toxin","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"BTG INTERNATIONAL INC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BTG INTERNATIONAL INC \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"BTG INTERNATIONAL INC \/ Undisclosed"},{"orgOrder":0,"company":"Catholic University of Korea","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Voltage-gated calcium channel","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Catholic University of Korea","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catholic University of Korea \/ Viatris","highestDevelopmentStatusID":"11","companyTruncated":"Catholic University of Korea \/ Viatris"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Steven Orebaugh","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Steven Orebaugh","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Steven Orebaugh"},{"orgOrder":0,"company":"Synedgen","sponsor":"J. Peter Rubin, MD","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Synedgen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Synedgen \/ J. Peter Rubin, MD","highestDevelopmentStatusID":"11","companyTruncated":"Synedgen \/ J. Peter Rubin, MD"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
Cerebrolysin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Brain Injuries, Traumatic.
Details :
Shenfu is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Shock, Septic.
Details :
NexoBrid (anacaulase-bcdb) is a topically administered biological product that enzymatically removes nonviable burn tissue, approved the treatment of severe burns.
Details :
Pregabalin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Rotator Cuff Injuries.
Details :
Ketamine is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Thoracic Injury.
Details :
Angiotensin II is a Peptide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Shock, Septic.
Details :
Centhaquine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Shock.
Reset All
Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.
